A major breakthrough in the internationalization of traditional Chinese medicine: Tongxinluo in the treatment of vascular diseases

The results of "a randomized, double-blind, placebo-controlled, multicenter clinical study on the application of Tongxinluo in the intervention of carotid plaque" led by academician Zhang Yun of Qilu Hospital, Shandong University, were published at the annual conference on interventional heart disease in China on March 29 The paper was published in the scientific reports, a subsidiary of nature, an international authoritative scientific journal The results show that Tongxinluo treatment can delay the progress of carotid artery mean intima-media thickness, plaque area and vascular remodeling index, reduce cardiovascular events, and has good safety Nature is one of the most influential international scientific and technological journals in the world It is rare to publish such a paper on the research of compound Chinese medicine Hundreds of mainstream media at home and abroad participated in the conference of evidence-based medicine research results of Tongxinluo intervention on carotid plaque Wang Guoqiang, President of the Chinese society of traditional Chinese medicine, Li Zhenji, vice president and Secretary General of the founding Committee of the World Federation of Chinese Medicine Societies, Chen Keji, academician of the Chinese Academy of Sciences, Zhang Yun, Wu Yiling, academician of the Chinese Academy of engineering, Professor Yang Yuejin, and other leaders and experts attended the press conference Wu Yiling, academician of Chinese Academy of engineering, made an academic report on the theoretical guidance and analysis of Tongluo drugs at the meeting President Wang Guoqiang pointed out that this press conference is of great significance Scientific and evidence-based research results are used to prove the effectiveness of traditional Chinese medicine in the intervention and treatment of cardio cerebrovascular diseases This topic is the research result of the combination of TCM collateral disease theory and scientific research methods It is a new mode of TCM innovation and a scientific innovation research mode This collaborative integration of Chinese and Western medicine, as well as joint research, the final results not only reflect the theoretical guidance of traditional Chinese medicine, but also rely on the evidence-based medicine evidence of Western medicine, which is recognized by western medicine Wang Guoqiang, President of the Chinese society of traditional Chinese medicine, made a speech at the meeting Vice President Li Zhenji said in his speech that this study is the first clinical evidence-based study in which traditional Chinese Medicine Intervenes in carotid plaque in the world This study confirmed that Tongxinluo, a traditional Chinese medicine, can safely and effectively delay the progress of carotid plaque area and vascular reconstruction, and confirmed the effectiveness and safety of traditional Chinese medicine again with evidence and internationally recognized evaluation methods The achievements of the research provide an example for carrying out evidence-based medicine research of traditional Chinese medicine and promoting the international spread of traditional Chinese medicine Li Zhenji, vice president and Secretary General of the World Federation of Chinese medicine, addressed the speech that carotid artery can reflect the health of human blood vessels In the 19th century, cassanis, a famous French doctor, had a famous saying: "people live with blood vessels." Blood vessel is a large system of human body Recently, the concept of "Pan blood vessel" has been put forward in the medical field The pathological changes of a region often reflect the unhealthy of the whole blood vessel system Carotid artery is a window reflecting human blood vessels, which is superficial and fixed, with high detection accuracy Now the ultrasound value of carotid artery is very large If there are sclerotic plaque, narrowing of lumen and other lesions in carotid artery, it means that the same lesions have occurred in other vessels, especially in cardio cerebrovascular diseases At present, the main indexes of carotid plaque detection include intima-media thickness, plaque area and vascular remodeling index The greater the intima-media thickness and plaque area, the higher the degree of arteriosclerosis, the larger the plaque volume, and the abnormal vascular remodeling index, indicating that the greater the vascular resistance caused by arteriosclerosis, the more difficult it is for blood to flow in the blood vessels The formation of plaque not only causes the blockage of blood vessels, causing angina, myocardial ischemia, etc., but also more importantly, the rupture of plaque, the formation of thrombus flowing with blood, coronary heart disease and myocardial infarction will occur if the cardiovascular system is blocked, and cerebral infarction will occur if the cerebrovascular system is blocked Therefore, for the subclinical patients without symptoms, early intervention of atherosclerosis, inhibition of plaque formation and reduction of plaque are of great significance for the prevention and treatment of cardiovascular and cerebrovascular diseases The evidence-based study of 1212 cases in 35 top three hospitals has proved that Tongxinluo capsule is a safe and effective drug for the prevention and treatment of angina pectoris, myocardial infarction, stroke and other cardiovascular and cerebrovascular diseases It has been used in clinical practice for more than 20 years and is taken by hundreds of thousands of patients with cardiovascular and cerebrovascular diseases every year As early as 2009, the international authoritative medical journal American Journal of physiology published a basic research paper on Tongxinluo to stabilize plaque The paper pointed out that Tongxinluo can reduce blood lipid level and inhibit systemic inflammation, increase the stability of atherosclerotic plaque and prevent its rupture In the comments, the editorial department commented that Tongxinluo "lit a light of hope for high-risk patients who may develop into coronary heart disease events in the future"! According to Academician Wu Yiling, the 1212 clinical evidence-based studies conducted by famous cardiovascular expert academician Zhang Yun this time provided accurate clinical data for clinicians to choose drugs, making this hope come true Evidence based medicine (EBM) is a scientific and fair evaluation method of drug efficacy recognized by the international medical community Led by academician Zhang Yun of Chinese Academy of engineering and led by Qilu Hospital of Shandong University, Tongxinluo capsule intervention on carotid plaque evidence-based medicine research was carried out in combination with Fuwai Hospital of Chinese Academy of Medical Sciences, Peking Union Medical College Affiliated to Huazhong University of science and technology and other 35 comprehensive top three hospitals in China This is the first large sample, double-blind intervention of traditional Chinese medicine preparation on carotid plaque in China , placebo-controlled multicenter clinical study The study was conducted in the World Health Organization international clinical trial The first level registration organization of the Registration Platform registered 1212 cases of carotid atherosclerotic plaques selected from 18 provinces in the country as the research object On the basis of clinical routine treatment, Tongxinluo capsule was added to observe the changes of such indexes as the thickness of the internal and middle membranes of bilateral carotid arteries, plaque volume and vascular remodeling index after 2 years of application, which made the study the largest in the world Evidence-based medicine research on the intervention of drugs on carotid plaque Zhang Yun, academician of Chinese Academy of engineering, released evidence-based research results of Tongxinluo intervention on carotid plaque at the meeting Academician Zhang Yun said that evidence-based research has obtained a series of exciting results, which confirmed that Tongxinluo can safely and effectively reduce carotid intima-media thickness, plaque area and vascular remodeling index in patients with subclinical arteriosclerosis, and the main cardiovascular events in patients receiving Tongxinluo treatment are significantly reduced, especially the incidence of unstable angina This means that Tongxinluo capsule can not only stabilize plaque and inhibit plaque formation, but also reverse the adverse effects of plaque on blood vessels and reduce the occurrence of angina, myocardial infarction, cerebral infarction and other major cardiovascular events A large number of previous basic and clinical studies have confirmed that Tongxinluo capsule can significantly protect the integrity of microvascular endothelial cells, significantly reduce the area of myocardial no reflow, resist atherosclerosis, stabilize plaque, relieve vasospasm, reduce the area of myocardial infarction, increase myocardial perfusion, inhibit ventricular remodeling and so on Therefore, the comprehensive evaluation of Tongxinluo capsule in the prevention and treatment of cardiovascular and cerebrovascular diseases is more advantageous than that of statins Professor Yang Yuejin said that the research was conducted by academician Zhang Yun in strict accordance with international evidence-based medicine research methods, principles and standards, so the results are reliable Although some people have disputes about traditional Chinese medicine, evidence-based medicine evidence is here It is believed that this study is of great significance to the construction of a healthy China, the acceleration of the aging society at present, and the realization of the Chinese dream in 2050 Professor Yang Yuejin of Beijing Fuwai Hospital highly praised the research results of Tongxinluo intervention on carotid plaque Tongxinluo evidence-based research was highly recognized by international authoritative journals On March 14, the evidence-based research paper of Tongxinluo intervention on carotid plaque was published in the scientific report (2017 influencing factor 4.122), a sub Journal of international authoritative scientific and technological journal Nature "Nature" is an internationally recognized journal with the highest academic reputation Its published articles are all high-level papers reviewed and checked by well-known experts all over the world, especially the papers on the research of compound Chinese medicine are rarely published Experts pointed out that there are many obstacles in the international promotion of traditional Chinese medicine On the one hand, it is difficult for foreign people to understand the theory of traditional Chinese medicine On the other hand, they have doubts about the composition of traditional Chinese medicine Therefore, the premise for Chinese medicine to go abroad can only be to prove its excellent efficacy through modern research At present, Tongxinluo capsule has won one second prize of national technology invention and two second prize of national science and technology progress It is a national basic drug, and has been listed in the guide to rational use of coronary heart disease 2018, the consensus of experts in the diagnosis and treatment of chronic cerebral ischemia with integrated traditional Chinese and Western medicine, the guide to clinical diagnosis and treatment of acute myocardial infarction 2016, and the diagnosis of coronary microvascular disease And the Chinese expert consensus 2017 and other guidelines / consensus, and was listed as the common Chinese medicine preparation for the treatment of coronary atherosclerotic heart disease in the textbook of integrated traditional and Western medicine In 2017, Tongxinluo capsule accounted for 6.92% of the oral Chinese patent medicines for cardiovascular diseases, becoming the basic drug for the treatment of cardiovascular and cerebrovascular diseases It has been registered and sold in South Korea, Vietnam, Russia, Canada, Singapore, Cambodia and other countries and regions, and approved by the Ministry of health of Vietnam to enter the national medical insurance catalog of Vietnam In clinic, many patients with coronary heart disease will be accompanied with arrhythmia, showing obvious symptoms such as panic and insomnia In addition to taking Tongxinluo capsule, it is also necessary to take Shensong Yangxin capsule which has significant therapeutic effect on tachyarrhythmia such as premature beat, atrial fibrillation and bradyarrhythmia such as tachyarrhythmia and bradyarrhythmia such as bradyarrhythmia syndrome Some patients with coronary heart disease have developed to a more serious stage of chronic heart failure, with symptoms such as fatigue and edema In this case, it is necessary to take Qiliqiangxin capsule which can not only strengthen the heart, diuresis, dilate blood vessels to treat the symptoms, but also inhibit the over activation of the neuroendocrine system, inhibit the ventricular remodeling to treat the root These innovative traditional Chinese medicines have a number of evidence-based medicine research evidence, are listed as recommended drugs by a number of guidelines, expert consensus, teaching materials, and the treatment effect has been widely recognized by the domestic and foreign medical circles and patients